IQVIA Holdings Inc. (NYSE:IQV) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned a consensus rating of “Moderate Buy” from the eighteen brokerages that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $251.0625.

A number of equities analysts have recently weighed in on the company. BMO Capital Markets started coverage on IQVIA in a research note on Thursday, November 13th. They issued an “outperform” rating and a $260.00 target price on the stock. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Barclays set a $230.00 target price on IQVIA in a research note on Monday, December 15th. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and increased their price target for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Finally, Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th.

IQVIA Stock Performance

NYSE IQV opened at $202.56 on Thursday. The company has a fifty day moving average price of $229.85 and a 200-day moving average price of $209.62. The firm has a market cap of $34.50 billion, a price-to-earnings ratio of 27.79, a PEG ratio of 2.07 and a beta of 1.37. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. IQVIA has a 1 year low of $134.65 and a 1 year high of $247.04.

Hedge Funds Weigh In On IQVIA

A number of large investors have recently made changes to their positions in the stock. Independent Advisor Alliance grew its holdings in IQVIA by 21.9% during the 4th quarter. Independent Advisor Alliance now owns 2,284 shares of the medical research company’s stock valued at $515,000 after buying an additional 410 shares in the last quarter. Legacy Financial Advisors Inc. boosted its position in shares of IQVIA by 16.8% in the fourth quarter. Legacy Financial Advisors Inc. now owns 5,560 shares of the medical research company’s stock valued at $1,253,000 after acquiring an additional 798 shares during the period. Atlantic Union Bankshares Corp grew its stake in IQVIA by 387.8% during the fourth quarter. Atlantic Union Bankshares Corp now owns 917 shares of the medical research company’s stock valued at $207,000 after acquiring an additional 729 shares in the last quarter. World Investment Advisors increased its holdings in IQVIA by 1.4% during the 4th quarter. World Investment Advisors now owns 81,682 shares of the medical research company’s stock worth $18,393,000 after acquiring an additional 1,162 shares during the period. Finally, Seelaus Asset Management LLC purchased a new stake in IQVIA in the 4th quarter worth approximately $251,000. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.